Login to Your Account


Proposed Part D rule changes could be bane to brand drugmakers

By Mari Serebrov
Washington Editor

Tuesday, January 7, 2014
With an eye on the bottom line, the Centers for Medicare & Medicaid Services (CMS) is proposing a Part D rule change that would tip the formulary scale in favor of generics and, in time, biosimilars.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription